Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Safusidenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nuvation Bio Reveals 2025 Financials And Business Update
    Nuvation Bio Reveals 2025 Financials And Business Update

    02 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nuvation-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-302701317.html

    PR NEWSWIRE
    02 Mar 2026
    Share Share
    Nuvation Bio Launches Global Phase 3 Trial For Safusidenib
    Nuvation Bio Launches Global Phase 3 Trial For Safusidenib

    09 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260204350848/en/Nuvation-Bio-Announces-Pivotal-Global-Phase-3-SIGMA-Trial-G203-for-Safusidenib-in-IDH1-Mutant-Glioma

    BUSINESSWIRE
    09 Feb 2026
    Share Share
    Nuvation Bio Publishes Positive Phase 2 Results For Safusidenib
    Nuvation Bio Publishes Positive Phase 2 Results For Safusidenib

    03 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251203703470/en/Nuvation-Bio-Announces-Publication-of-Positive-Phase-2-Study-Results-for-Safusidenib-for-the-Treatment-of-Grade-2-IDH1-Mutant-Glioma-in-Neuro-Oncology

    BUSINESSWIRE
    03 Dec 2025
    Share Share
    Nuvation Enrolls 1st Patient in Randomized Study of Safusidenib
    Nuvation Enrolls 1st Patient in Randomized Study of Safusidenib

    04 Nov 2025

    // PRESS RELEASE

    https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Enrolls-First-Patient-in-Global-Randomized-Study-of-Safusidenib-for-Maintenance-Treatment-of-High-Grade-IDH1-Mutant-Glioma/default.aspx

    PRESS RELEASE
    04 Nov 2025
    Share Share
    Nuvation Bio Enrolls 1st Patient in Global Study of Safusidenib
    Nuvation Bio Enrolls 1st Patient in Global Study of Safusidenib

    23 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251023640173/en/Nuvation-Bio-Enrolls-First-Patient-in-Global-Randomized-Study-of-Safusidenib-for-Maintenance-Treatment-of-High-Grade-IDH1-Mutant-Glioma

    BUSINESSWIRE
    23 Oct 2025
    Share Share
    Nuvation Bio Appoints Philippe Sauvage As Chief Financial Officer
    Nuvation Bio Appoints Philippe Sauvage As Chief Financial Officer

    07 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241007470241/en

    BUSINESSWIRE
    07 Oct 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.